Egyszerű nézet

dc.contributor.author Barna, István
dc.date.accessioned 2016-07-21T13:13:38Z
dc.date.available 2016-07-21T13:13:38Z
dc.date.issued 2006
dc.identifier.citation pagination=1019-1023; journalVolume=147; journalIssueNumber=22; journalTitle=ORVOSI HETILAP;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/3384
dc.description.abstract The renal impairment due to hypertension causes the disturbance of the renin-angiotensin-aldosterone system which is accompanied with increased activity of the sympathetic nervous system. Administration of angiotensin-converting enzyme inhibitors decreases the production of angiotensin II, secretion of aldosterone, sodium and water retention and peripheral vascular resistance which altogether lead to the reduction of blood pressure. The nephro-protective efficacy of angiotensin-converting enzyme inhibitors was also proved by plenty of extensive international trials both in diabetic and non-diabetic patients with renal diseases. On evidence based medicine we may consider angiotensin-converting enzyme inhibitors and angiotensin receptor blockers--provided there are no contraindications as the standard therapy in all hypertensive and renal diseases.
dc.relation.ispartof urn:issn:0030-6002
dc.title Angiotenzinkonvertáló enzim-gátlók a vesevédelemben [ACE-inhibitors in renal protection]
dc.type Journal Article
dc.date.updated 2016-04-27T09:29:04Z
dc.language.rfc3066 hu
dc.identifier.mtmt 1593239
dc.identifier.pubmed 16913091
dc.contributor.department SE/AOK/K/I. Sz. Belgyógyászati Klinika


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet